Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07566104 · ClinicalTrials.gov registry record · Phase 2
Group PACBT for Depression
A Phase 2 study, sponsored by University of California, Los Angeles.
- Not yet
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT07566104 is a Phase 2 study that has not yet begun recruiting, run by University of California, Los Angeles. The registered enrollment target is 30 participants.
The verdict
NCT07566104, a Phase 2 study, has not yet begun recruiting, sponsored by University of California, Los Angeles.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
This study will seek to determine the (1) acceptability and (2) feasibility of psilocybin as an adjunct to cognitive-behavioral therapy, delivered as a group treatment (G-PACBT) for major depressive disorder and (3) explore the clinical effects of G-PACBT on depressive symptoms and psychosocial functioning.
Interventions
- DRUG Psilocybin (drug)
- BEHAVIORAL Group Cognitive Behavioral Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2027-01 |
| Est. Completion | 2028-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07566104
The ClinicalTrials.gov registry entry for NCT07566104 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Psilocybin (drug) is the first listed.
NCT07566104 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07566104 about?
NCT07566104 is a clinical study titled "Group PACBT for Depression". This study will seek to determine the (1) acceptability and (2) feasibility of psilocybin as an adjunct to cognitive-behavioral therapy, delivered as a group treatment (G-PACBT) for major depressive disorder and (3) explore the clinical effects of G-PACBT on depressive symptoms and psychosocial func...
What is the current status of trial NCT07566104?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2027-01. Estimated completion is 2028-12.
What interventions are being tested in trial NCT07566104?
The interventions under investigation include: Psilocybin (drug) (DRUG), Group Cognitive Behavioral Therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT07566104?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.